

#### **INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES**

#### INTRODUCING BIOSURANCE™

We understand the unique nature of Life Science businesses. Drug developers, CROs, CMOs and contract research service providers work together to drive forward the discovery and development of new therapeutic products.

BioSurance™ R&D is an innovative insurance product that allows companies in the R&D chain to cover their unique risk exposures in the context of their business and funding models.

#### DAMAGE TO R&D PROPERTY

Traditional "fire & perils" policies only go part way to covering the potential for damage to R&D Property. BioSurance™ R&D goes much further, providing cover:

- At premises throughout the supply chain and whilst in transit
- With a wide definition of "stock" including documents and electronic data
- For damage or spoilage resulting from power outage, equipment breakdown, contamination and ideologically motivated attack
- For full stock re-creation costs, including those attached to repeating completed R&D
- For undamaged property when condemned by a competent authority

# "FLEXIBLE FIRST LOSS" BUSINESS INTERRUPTION COVER

We recognise the importance of reaching milestones within budget and that R&D expenditure tends to ramp up in the approach to significant events such as clinical trials. BioSurance™ R&D therefore provides flexible and comprehensive Business Interruption cover. Benefits include:

- Disruption due to damage at supply chain premises, even if there is no damage to the insured's property
- Loss or damage to stock in transit
- A first loss sum insured that can compensate for lost revenue, unproductive R&D expenditure, committed costs and project delay costs without sub-limit
- No weekly sub limit

#### LIABILITY TO THIRD PARTIES

BioSurance™ R&D provides broad, specialist liability cover, including:

- Product and services liability covering third party property damage, bodily injury and financial loss on a seamless basis ensuring no gaps or overlaps
- · Clear, unambiguous cover for breach of a client contract
- Clinical trial insurance available for single trials, or on an annual multi trial basis with the cover limit separate to, or aggregated with, product and services liability

- Comprehensive general liability, including pollution and contamination, tenants' legal liability, employee benefits liability, non owned and hired auto and medical expenses
- Cover for suits brought anywhere in the world as standard

#### **SERVICE**

We recognise that Life Science companies want to buy their insurance quickly and simply. That's why our policy is backed up by exceptional service levels featuring:

- Most quotes provided within 48 hours
- · A fast track service for urgent submissions
- · Most policies issued within 24 hours of binding

All this at very competitive prices. To obtain a quote all we need is the completed BioSurance $^{\text{TM}}$  R&D Application Form.



CFC Underwriting Ltd is Authorised and Regulated by the Financial Conduct Authority ©1999-2010 CFC Underwriting Ltd, All Rights Reserved



**INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES** 

# **BioSurance® R&D Application Form**

BioSurance® R&D is an insurance package designed specifically for the Life Science sector. The policy provides comprehensive protection throughout a company's life-cycle including property damage, the financial impact of interruption to activities, clinical trials and the legal liabilities of the company and its directors. Every aspect of the cover has been specifically tailored to the unique risk exposures and business models of Life Science companies.



CFC Underwriting Limited

85 Gracechurch Street

London EC3V 0AA

United Kingdom

T: +44 (0) 207 220 8500

F: +44 (0) 207 220 8501

E: enquiries@cfcunderwriting.com

W: www.cfcunderwriting.com



## **INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES**

### **APPLICATION FORM**

#### INTRODUCTION

The purpose of this application form is for us to find out who you are and to obtain information relevant to the cover provided by the BioSurance® R&D policy. Completion of this application form does not oblige either party to enter into a contract of insurance.

Insurance is a contract of utmost good faith. This means that the information you provide in this application form must be complete, accurate and not misleading. It also means that you must tell us about all facts and matters which may be relevant to our consideration of your application for insurance. Any failure by you in this regard may entitle us to treat this insurance as if it never existed. If a contract of insurance is agreed between you and us this application form will form the basis of the contract.

Important: Some of the cover provided by this policy is on a claims made basis. This means that a claim must be first made against the Insured and notified to us during the period of the policy to be covered and a claim will not be covered if it arises out of any actual or alleged wrongful act occurring before the Retroactive Date.

#### HOW TO COMPLETE THIS FORM

Whoever fills out the form must be a principal, partner or director of the applicant firm and should make all the necessary enquiries of their fellow partners, directors and employees to enable all the questions to be answered.

If you require any extra space to complete the answers to questions contained within this application form please continue your response in the Additional Information section at the back of the form. Once you have completed the form please return directly to your insurance agent.

#### SECTION I: COMPANY DETAILS

I.I P	Please provide the following det	tails:	
	Insured company:		
	Contact name:		
	Address:		
	ZIP code:		
	Telephone:	Email address:	
	Fax:	Website:	
_			
1.2 P	lease state when your company	ıy was established:	
1.3 P	lease briefly describe below the	ne nature of your business activities:	
If	you have a brochure, or compan	ny literature, please attach to this form.	

Name and Address	Details of Usage
ase continue on a separate sheet if more than two premises are to be ase provide details of the premises of your supply chain partnepse where you require cover for damage to your property and the siness activities:	ers that carry out significant work on your behalf, in
Details of usage:	
	ZIP code:
PREMISES 2 Address:	
Details of usage (e.g. labs, storage, offices etc.):	
	ZIP code:
Address:	
PREMISES I	
ase provide below details of your premises:	
ON 2: PREMISES DETAILS	
ase state the number of employees:	

b) F	Free from cracks or other signs			_	
а	and have not previously suffered	d damage by any of these caus	es?	Yes	No
c) I	In an area free from flooding an	d not near the vicinity of any	rivers, streams or tidal waters?	Yes	☐ No
d) I	In a good state of repair?			Yes	□ No
e) S	Self contained with a lockable e	ntrance door?		Yes	∐No
f) F	Protected by fire and intruder a	larms that are subject to an a	nnual maintenance contract?	Yes	No
			tection of your premises (including left unatte		
g) H	Heated by a conventional electr	ric, gas, oil or solid fuel heating	g system?	Yes	No
	Fitted with electrical installation electrician and any defect remedent		every 5 years by a qualified	Yes	No
	Lifts, boilers, steam and pressur of the statutory requirements?	e vessels inspected and appro-	ved to comply with all	Yes	□No
2.4 If ar	any of the premises listed in 2.1  Address	and 2.2 contain composite or  Are panels exterior or interior?	sandwich panels, please provide Type of Panel (Make, model, core material)	details:  Are products LPS or FMRC4880 approved	(1994)
SECTION SECTION		Are panels exterior or interior?	Type of Panel (Make, model, core material)	Are products LPS or FMRC4880	(1994)
SECTION If 'y	Address  ON 3: ACTIVITIES  you directly work with, or stor	Are panels exterior or interior?	Type of Panel (Make, model, core material)	Are products LPS or FMRC4880 approved	(1994) }? No

2.3 Are all of the premises:

	If 'yes', please ans	swer the following:				
	a) What proport	ion of stock is tempera	ture sensitive?			%
		es/freezers less than 3 y go to question 3.2 c)	vears old?		Yes	No
	If no, do you h	nave a maintenance cont	tract in place?		Yes	No
	If yes, does the	e maintenance contract	provide free parts and labor?	N/A	Yes	No
	Does the mair takes place at		in a provision that an inspection	□ N/A	Yes	No
	c) Is electricity d	elivered by underground	d cables, with no overhead power lines in the im	mediate vicinity	? Yes	No
	d) Do all fridges	/ freezers have back up	power generators?		Yes	No
	If 'yes', how m	any hours back up is pr	ovided?			Hours
	e) Do you have a	ın alarm system that act	ivates if the temperature falls outside the prescr	ribed range?	Yes	No
	f) Is the alarm sy	stem monitored by a th	nird party central station?		Yes	No
	g) Is stock duplic	ated in more than one	freezer on the same site?		Yes	No
	h) Is stock duplic	ated in more than one	freezer at different sites?		Yes	No
	i) Do you have a	formal Business Contin	nuity Plan for a power outage or failure in storag	ge arrangements	? Yes	No
3.3	Are specialist cou	riers utilized for stock	transport?		Yes	No
	If 'no', please pro	vide details of the arran	gements:			
3.4	Please state stock	c consignment values:				
			Annual value	Maximum value	of one cons	ignment
	Domestic:					
	Outside (dome					
	Elsewhere in t	he world:				
3.5	, ,	rt stock to areas where ovide details below:	the government currently advises against travel?	,	Yes	No
3.6	Are you involved	with R&D of your own	producte)		Yes	□No
3.0	If 'no', please go to	•	products:		les	
3.7	Please state your	annual gross expenditu	re:			
3.8	Please state what	proportion of your and	nual gross expenditure is attributable to:			
	Fixed internal	cost (including payroll):				%
	Variable intern	nal cost (such as lab con	sumables):			%
	Contractually	committed payments fo	r services to third parties:			%
			majeure' provisions to your benefit:			

Supplier	name	Nature of reliance	Conting	ency plans
10 Do you receive incom  If 'no', please go to sect  If 'yes', please state th	ion 4.	services provided to third parties?	,	Yes N
Location of client  Domestic: Elsewhere in the w	F	Last complete financial year Products Services	Current fina Products	ncial year (estimate) Services
II Please give details of Client name	the 3 largest contract	nts that you have carried out in the Nature of work undertaken for this contract	e last 3 years:  Your annual income from this contract	Start Completion date date
12 What approximate pe	ercentage of your inco	ome, in your current financial year, v	will be paid to sub-contrac	:tors? %
13 Will sub-contractors	carry the following i	nsurance:		
a) Products liability fo	or CMOs?			Yes N
b) Errors and Omission	ons for CROs, contr	act research service providers and	other consultants?	Yes No
c) Medical malpractic conducting your cl		ernment liability) for clinical investi	igators	Yes No
14 Will your products b	e marketed for huma	an consumption in the next 12 mc	onths?	Yes No
If 'no', please go to sec	tion 4.			
If 'ves' blease attach l	iterature for each of th	nese products, including brochures, te	echnical literature, sale con	ditions
ij yes, piedse detacii ii				

3.16	Are these products:		
	a) Vaccines?	Yes	No
	b) Gene therapy?	Yes	No
	c) Cell therapy?	Yes	□ No
	d) Acutane, amenorone forte, bupropion, canthaxanthin, cisapride, danthron, debendox, DEHP, dexfenfluramine, diazepines, dicyclomine, diethylstilbestrol (DES), dioxins, ephedrine, fenfluramine, fibrates, germanium, halogenated 8, hydroxy quinolines, hydroquinone, isotretinoin, lotronex, l-tryptophan, methylphenidate, nefazodone, oxazepines, paxil, pertussis vaccine, phenfluramine, phentermine, phenylpropanolamine (PPA), piper methysticum, primodos, prozac, remoxipride, retinoids, risperidone, serzone, silicone gel used as part of an injection or as part of an implantable device, statins, swine-flu vaccine, thalidomide, thiazepines, thimerosol or thimersal, tretinoin, troglitazone, tryptophan?	Yes	ΠN
	e) Implantable medical devices?	Yes	∐N <sub>0</sub>
	f) Skin whitening products?	Yes	∐N•
	g) Birth control products or devices?	Yes	N
	If 'yes' to any of the above, please provide details:		
3.17	Could the failure of these products or services result in:		
	a) Loss of life or injury to a person?	Yes	Пи
	b) Damage or destruction to physical property?	Yes	N
	c) Significant third party financial loss?	Yes	_ □N
	If 'yes' to any of the above, please provide details:		
3.18	Is the delivery of these products and services time critical to the third parties using them (such as a clinical trial)?	Yes	□N
	If 'yes', please provide details:		

SEC	CTION 4: CONTRACT MANAGEMENT		
4.1	Is all work carried out (by you, or for you) under a written contract?	Yes	No
4.2	Are all contracts reviewed by independent, qualified legal advisers?	Yes	No
	If 'no', please outline the procedures used for developing and reviewing contracts:		
4.3	Are rights of recourse retained against CMOs, CROs, clinical investigators and all other supply chain partners?	Yes	No
	If 'no', please explain why:		
4.4	In your written contracts do you ever accept liability for consequential loss or financial damages greater than the value of the contract?	Yes	No
	If 'yes', please provide details:		
4.5	Do your written contracts ever contain 'Hold Harmless' or 'Indemnification' clauses in which you accept liability for loss of life, injury, property damage, or financial losses in circumstances other than where they are caused by your negligence?	Yes	No
	If 'yes', please provide details:		
4.6	In your written contracts, do you ever provide guarantees of products or services?	Yes	No
	If 'yes', please provide details:		

# **SECTION 5: CLINICAL TRIALS**

Only complete this section if you require cover for clinical trials.

In respect of each of the clinical trials listed below, please attach the following (in English): a) Trial Protocol

5.2

5.3

5.4

5.5

- b) Patient Information
- c) Patient Informed Consent form
  d) A list of the Clinical Investigator sites

-	DI.			1	•			•	1			
5 1	Please	provide	helow	details	∩†	completed	trials	tor	which	COVER	10	required
9.1	1 ICasc	provide	DCIOTT	dectails	01	Completed	ti iais	101	**!!!	COVCI	13	i cquii cu.

rotocol number and description	Date treat	ment completed	Nu	mber of s	ubjects	Country	/
	MM /	DD / YY					
	MM /	DD / YY					
	MM /	DD / YY					
	MM /	DD / YY					
Please provide below the details rimary cover is required:	of ongoing trials, o	or trials that are exp	ected to	commend	e in the next	: 12 months,	for w
rotocol number and description	Start date	e Expected er	nd date	Number	of subjects	Countr	у
	MM / DD /	YY MM / DD	/ YY				
	MM / DD /	YY MM / DD	/ YY				
	MM / DD /	YY MM / DD	/ YY				
rimary insurance policy will be i	in place and therefo	r trials expected to ore excess cover onl	commenc y is requi	ired:			
rimary insurance policy will be i	of ongoing trials, or	trials expected to o	commenc y is requi		ext 12 month Country	ns, for which Insurer and number underlying	d polic
rimary insurance policy will be i	of ongoing trials, or in place and therefo	r trials expected to ore excess cover onl	commenc y is requi	ired: nber		Insurer and number	d polic
rimary insurance policy will be i	of ongoing trials, or in place and therefo Start date	e trials expected to ore excess cover onl  Expected end date	commenc y is requi	ired: nber		Insurer and number	d polic
rimary insurance policy will be i	of ongoing trials, or in place and therefore Start date	Expected end date	commenc y is requi	ired: nber		Insurer and number	d polic
rimary insurance policy will be i	of ongoing trials, or in place and therefore Start date  MM / DD / YY  MM / DD / YY	Expected to one excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY	commenc y is requi	ired: nber		Insurer and	d polic
Please provide below the details rimary insurance policy will be in the protocol number and description and description when the protocol number are description and the protocol number and description are you the sponsor in respect of the protocol number and description are you the sponsor in respect of the protocol number and description are you the sponsor in respect of the protocol number and description are you the sponsor in respect of the protocol number and description are your description.	of ongoing trials, or in place and therefore  Start date  MM / DD / YY  MM / DD / YY  MM / DD / YY	Expected to core excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	ommenc y is requi Nun of sul	ired: nber		Insurer and	d polic
rimary insurance policy will be in rotocol number and description and description are you the sponsor in respect of	of ongoing trials, or in place and therefore  Start date  MM / DD / YY  of each of the clinic	Expected to core excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	ommenc y is requi Nun of sul	ired: nber		Insurer ann number underlying	d polic
rimary insurance policy will be in rotocol number and description and description are you the sponsor in respect of	of ongoing trials, or in place and therefore  Start date  MM / DD / YY  of each of the clinic	Expected to core excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	ommenc y is requi Nun of sul	ired: nber		Insurer ann number underlying	d polic
rimary insurance policy will be introduced in the introduced number and description	of ongoing trials, or in place and therefore  Start date  MM / DD / YY  of each of the clinic	Expected to core excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	ommenc y is requi Nun of sul	ired: nber		Insurer ann number underlying	d polic
rimary insurance policy will be in rotocol number and description and description are you the sponsor in respect of	of ongoing trials, or in place and therefore  Start date  MM / DD / YY  of each of the clinic	Expected to core excess cover onl  Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	ommenc y is requi Nun of sul	ired: nber		Insurer ann number underlying	d polic

CFC Underwriting Limited is Authorised and Regulated by the Financial Conduct Authority ©1999-2014 CFC Underwriting Ltd, All Rights Reserved

5.6	In respect of the clinical trials listed above, will any of the following be tested:		
	a) Vaccines?	Yes	No
	b) Gene therapy?	Yes	No
	c) Cell therapy?	Yes	No
	d) Acutane, amenorone forte, bupropion, canthaxanthin, cisapride, danthron, debendox, DEHP, dexfenfluramine, diazepines, dicyclomine, diethylstilbestrol (DES), dioxins, ephedrine, fenfluramine, fibrates, germanium, halogenated 8, hydroxy quinolines, hydroquinone, isotretinoin, lotronex, l-tryptophan, methylphenidate, nefazodone, oxazepines, paxil, pertussis vaccine, phenfluramine, phentermine, phenylpropanolamine (PPA), piper methysticum, primodos, prozac, remoxipride, retinoids, risperidone, serzone, silicone gel used as part of an injection or as part of an implantable device, statins, swine-flu vaccine, thalidomide, thiazepines, thimerosol or thimersal, tretinoin, troglitazone, tryptophan	Yes	No
	e) Implantable medical devices?	Yes	No
	f) Skin whitening products?	Yes	No
	g) Birth control products or devices?	Yes	No
	If 'yes' to any of the above, please provide details:		
5.7	In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the research subjects under 16 years?  If 'yes', please provide details:  In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the	Yes	□ No
	research subjects women of child bearing age?	ies	
	If 'yes', please provide details:		
5.9	Are all clinical trials conducted in accordance with all relevant local laws and regulations?  If 'no', please explain why:	Yes	No
	The peace explain my.		

5.10	In respect of all completed and ongoing trials, have you:			
	a) Made all necessary filings?	Yes	No	
	b) Received all required authorisations?	Yes	No	
	c) Had the protocol approved by an independent Ethics Committee?	Yes	No	
	If 'no' to any of the above, please explain why:			
5.11	·	Yes	No	
	If 'yes', please provide details:			
5.12	Have you stopped or suspended any clinical trials for safety reasons?	Yes	□No	
	If 'yes', please provide details:			
	/sex, preuse previde estation			
5.13	Have any research subjects suffered death, injury, disease or illness (whether physical or mental)			
	as a result of participation in a clinical trial sponsored by you, in the past 5 years?	Yes	No	
	If 'yes', please provide details:			
SEC	CTION 6: COVER LIMITS & SUMS INSURED			
6.1	Would you like cover for damage to your property?	Yes	No	
	If 'no', please go to question 6.7.			
	If yes, please attach information regarding the value of the following property, including estimated maximum volume time where applicable, at the premises listed in question 2.1 and 2.2:	alues at risk at	any	
	a) Buildings			
	b) Tenants improvements, fixtures & fittings c) Laboratory equipment			
	d) Fixed electronic equipment e) Portable electronic equipment			
	f) Lab consumables and R&D Stock (including the cost of materials and other re-creation costs) g) Third party stock in your custody and control			
	h) Research animals (showing the total value and the estimated maximum value of a single animal) i) Any other property not listed above			

6.2	Would you like the policy to cover any	of the following:			
	a) Spoilage of perishable stock?			Yes No	
	b) Pollution or contamination?			Yes No	
	c) Machinery breakdown?			Yes No	
	d) Property in transit?			Yes No	
	e) Terrorism?			Yes No	
	f) Ideologically motivated attack (that i an act of terrorism by the governmen			Yes No	
6.3	Would you like business interruption c	over?		Yes No	
	If 'yes', please state the 'First Loss' sum	n insured required:			
6.4	Please state the sublimits required for listed in question 2.2:	business interruption follo	wing damage at the premise	s of your supply chain partners	
	Supply chain partne	r name	Business int	erruption sublimit	
6.5	Please state the indemnity period requ	ired (6 - 24 months):		Months	
6.6	Would you like cover for General Liabi	lity?		Yes No	
	If 'yes', please state the limit of liability	required:			
6.7	Would you like cover for products and	services liability?		Yes No	
	If 'yes', please state the limit of liability	required:			
SEC	TION 7: CLAIMS EXPERIENCE	& INSURANCE HIST	ORY		
7.1	Please provide details of your current i		<del>o</del> ni		
	Type	Expiry date	Retroactive date	Insurer	
	Property and business interruption:	r/ -===	N/A		
	General Liability:		N/A		
	Products liability:				
	Errors and Omissions:				
	Clinical trials:				
	Cimical triais:				

7.2 Regarding all of the types of insurance to which this application form relates, AFTER ENQUIRY: a) are you aware of any loss or damage, whether insured or not, that has occurred to any of the Companies to be insured (or to any existing or previous business of the partners or directors of any of the Companies to be insured) within the last 5 years, or b) are you aware of any circumstances which may give rise to a claim against any of the Companies to be insured or any partners or directors thereof, or c) have any claims or cease and desist orders been made against any of the Companies to be insured, or partners or directors thereof, or d) have any partners or directors of the Companies to be insured been found guilty of any criminal, dishonest or fraudulent activity or been investigated by any regulatory body? No With reference to questions a, b, c and d above: Yes If the answer to the above is 'yes', then please attach full details including an explanation of the background of events, the maximum amount involved / claimed, the status of the claim(s) or circumstance(s) and any reserve(s) or payment(s) made by you and / or by Insurers, and the dates of all developments and payments. **SECTION 8: DECLARATION** · I declare that after proper enquiry the statements and particulars given above are true and that I have not mis-stated or suppressed any material fact. · I agree that this application form, together with any other material information supplied by me shall form the basis of any contract of insurance effected thereon. · I undertake to inform Underwriters of any material alteration to these facts occurring before the completion of the contract. Signed: Full name:

Date:

Position held at insured:

ADDITIONAL INFORMATION:





# **INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES**



CFC Underwriting Limited 85 Gracechurch Street London EC3V 0AA United Kingdom T: +44 (0) 207 220 8500 F: +44 (0) 207 220 8501

E: enquiries@cfcunderwriting.com
W: www.cfcunderwriting.com